Aerovate Therapeutics Inc. (AVTE) Announces 1-for-35 Reverse Stock Split

Aerovate Therapeutics Inc. (AVTE) closed flat today, marking a stable trading session for the company's stock.

Aerovate Therapeutics Inc. has announced a 1-for-35 reverse stock split in connection with a proposed merger with Jade Biosciences. This corporate action is expected to be completed between April 28 and May 2, 2025. The reverse stock split is a strategic move aimed at increasing the stock's price per share, which could potentially attract more investors and improve liquidity.

Additionally, Aerovate Therapeutics, Inc. (AVTE) will be de-listed from the MIAX Options Exchange, MIAX Pearl Options Exchange, and MIAX Emerald Options Exchange. This de-listing is part of the company's broader restructuring efforts, which may include cost-cutting measures and a focus on core operations. The de-listing could impact trading activity and investor sentiment, as options trading provides additional avenues for market participation and speculation.